Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 10/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.33 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25549221 | 0.93 | CXCR2 (0.41) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL23460926 | 0.91 | CXCR2 (0.43) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL38666109 | 0.91 | CXCR2 (0.43) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL23460924 | 0.91 | CXCR2 (0.43) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL23461110 | 0.90 | KCNK2 (0.44) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL38147087 | 0.90 | KCNK2 (0.44) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL23461108 | 0.90 | KCNK2 (0.44) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL23460950 | 0.89 | CXCR2 (0.50) | CXCR2PTPN2PTPN1PYGLCYP2C9 | |
| SCHEMBL23460718 | 0.89 | CXCR2 (0.50) | CXCR2PDE2APTPN2PTPN1PTPN7 | |
| SCHEMBL23460953 | 0.89 | CXCR2 (0.50) | CXCR2PTPN2PTPN1PYGLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885PDE2A 356/4885PTPN2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.